Cantor Fitzgerald analyst Louise Chen reaffirms her Overweight rating on Eli Lilly with a $100 price target after speaking with four physicians to discuss the company's cardiovascular outcomes study for Trulicity known as Rewind. Most of the physicians expect a positive outcome for Rewind, Chen tells investors in a research note. A favorable outcome could increase Trulicity prescriptions by 20%-30% or by "multiples of current sales," the analyst contends. As such, she believes that "significant upside remains in the drug, if the doctors are right." Chen expects top-line data by year-end 2018.